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Nephrogenic systemic fibrosis (NSF) is characterized by red
skin areas or plaques that over several weeks successively
develop to painful thickened skin with a ‘woody’ texture,
resembling ‘peau d’orange’. Starting at the extremities, it
may spread to the trunk, and may progressively inhibit
flexion of adjacent joints. In skin biopsies of affected areas,
thickened collagen bundles, mucin deposition, and
proliferation of fibroblasts and elastic fibers are seen.
Originally described as nephrogenic fibrosing dermopathy
(NFD) because of its primarily cutaneous manifestation, this
entity was then named NSF because of systemic involvement
of other organs like lungs, myocardium, or striated muscles.
The pathogenesis of the disease is not yet known, but our
observations suggest a close association between
development of NSF and exposure to gadolinium-containing
contrast agents, thereafter confirmed by other authors.
Recently, gadolinium was demonstrated to be detectable in
skin tissue samples of affected patients. In this short review,
the development of NSF and its sequential association with
the exposure to gadolinium-containing contrast agents is
presented. The mechanisms likely to cause NFD/NSF are
discussed.
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Nephrogenic systemic fibrosis (NSF),1–3 named nephrogenic
fibrosing dermopathy (NFD) at first in 2001,4 is an acquired
disease, yet considered idiopathic. NSF is observed in patients
with renal insufficiency, most but not all of whom have
undergone dialysis for renal failure.4,5 Since its recognition in
1997 and first description in literature in 2000,6 more than
215 cases have been reported worldwide. Among others, an
association of NSF with coagulation abnormalities, recent
vascular surgery or intervention4 (e.g. fistula operation and
angioplasty), administration of erythropoietin7 or angioten-
sin converting enzyme inhibitors,8 and presence of antiphos-
pholipid antibodies9 has been discussed by several authors so
far, but the pathogenesis of this entity is still not clearly
identified.
Clinically, NSF is characterized by initial swelling of distal
parts of the extremities with subsequent thickening, indura-
tions, and hardening of the skin in the following weeks.
Distinct nodules can also be seen (Figures 1 and 2). The
(distal) extremities are the most common area of involve-
ment, followed by the trunk. The face is almost never
involved.4 The disease may be progressive and lead to skin
stiffness and serious physical disability. Skin biopsy is
required to confirm the diagnosis of NSF and to differentiate
from other fibrosing skin disorders. There are specific
histopathologic features, namely thickened dermis (Figure 3)
with bundles of collagen and surrounding clefts, mucin
deposition (Figure 4), and a proliferation of fibroblasts and
elastic fibers. Signs of inflammation are absent, which makes
this disorder a distinct entity.10
Recently, we reported on the observation of a series of five
patients, who had received gadolinium-containing contrast
agents for magnetic resonance imaging (MRI) examinations
and subsequently developed NSF within 2–4 weeks.11 Our
findings were substantiated by a Danish group shortly
thereafter, who presented data on 13 patients with NSF
following gadodiamide administration.12 These authors
calculated an odds ratio of 32.5 to acquire NSF when
exposed to gadodiamide. These findings have prompted the
United States Food and Drug Administration (FDA) to issue
a public health advisory regarding gadolinium-containing
contrast agents and a possible link to development of NSF.13
Most recently, official authorities (European Medicines
Agency (EMEA), Pharmacovigilance Working Party
(PhVWP), and the Committee on Medicinal Products for
human Use – (CHMP)) as well as the manufacturers of
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Gadodiamide (Omniscans, Amersham Health, Oslo, Norway
and Carrigtohill, County Cork, Ireland) have considered
administration of gadodiamide to be contraindicated in
patients with a glomerular filtration rate (GFR) less than
30 ml/min/1.73 m2 as well as in liver transplant recipients.
This mini review summarizes the current view of the
possible link between exposure to gadolinium-containing
contrast media and development of NSF.
GADOLINIUM
Gadolinium (Gd), with atomic number 64, belongs to the
lanthanide series. The trivalent gadolinium ion (Gd3þ ) is
very close to the divalent calcium ion as reflected by size,
bonding, coordination, and donor atom preference.14
Gadolinium has unusual superconductive and ferromagnetic
properties, is used in microwave applications, and Gd
compounds are used to make phosphors in color TV sets.
Non-complexed gadolinium is unsuitable for clinical use, as
it may precipitate and is retained for long periods in the
body. Insolubility and toxicity of Gd is largely eliminated by
forming either macrocyclic or linear chelates, for example
Gd-DTPA (diethylene triaminepentaacetic acid).15
The biochemical effects induced by gadolinium salts, for
example GdCl3 (gadolinium chloride), may occur through
interference with intracellular calcium-dependent processes
and calcium entry into cells. Gadolinium presumably
displaces calcium ions from cation-binding sites on cellular
membranes and binds to and activates the extracellular
calcium-sensing receptor, which is present on various tissues
like fibroblasts, kidney, parathyroid glands, hepatocytes, and
pancreas. GdCl3 can form mineral emboli in the circulation,
which are deposited in the capillary bed of organs and are
taken up by phagocytosis.16 Electron-dense deposits found in
various organs have been shown to contain gadolinium and
may consist of a complex of gadolinium and phosphate.17
Free Gd ion also blocks macrophage function and may cause
cell death, which is likely to occur as a result of initial
phagocytosis of gadolinium particles.17 This process is likely
Figure 1 | Clinical picture of long-standing nephrogenic systemic
fibrosis. A patient with NSF of about 3 years: diffuse thickening,
induration, and hyperpigmentation of lower legs with inhibition of
joint flexion.
Figure 2 | Clinical picture early in the course of nephrogenic
systemic fibrosis. Right leg of a patient with NSF lasting 4 weeks
only: after diffuse swelling of the skin, erythematous papules and
nodules became apparent.
Figure 3 | Skin biopsy of the right leg of an affected patient. The
dermis is thickened and demonstrates swollen collagen bundles with
surrounding clefts and spindle cell proliferation. Interstitial mucin
deposition is frequently present (hematoxylin and eosin stain).
Figure 4 | Fibrosis (Magnified Figure 3). Fibrocytes (yellow arrow)
and swollen collagen bundles (green arrow) with surrounding clefts
are shown. Interstitial mucin (red arrows) is increased, inflammatory
cells are absent. The light blue arrow indicates degenerated
collagen fibers (hematoxylin and eosin stain).
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to be mediated by pinocytosis-based internalization. It has
been proposed that lanthanide ions may leak into cells
through pores induced by lanthanide ions bound to the
membrane.18 The sequence of events during Gd permeation
through the cell membrane into erythrocytes starts with Gd
binding to membrane phospholipid, followed by a transfer to
membrane proteins and ends with a phase transition in the
lipid bilayer and aggregation of membrane proteins that
results in the perforation of the membrane.18
GADOLINIUM-CONTAINING CONTRAST MEDIA
Gadolinium-containing contrast agents are widely used and
have been thought to be safe, even in patients with impaired
renal function. The frequency of minor side effects is low.
Some pharmacologic characteristics of several Gd-containing
contrast agents that are FDA-approved are given in
Table 1.19,20 Although Gd-containing contrast agents are
rapidly cleared with a half-life of 1.3 h in healthy volunteers,
according to pharmacokinetic studies, the half-life is
markedly prolonged up to 30–120 h in chronic renal failure.
In hemodialysis and peritoneal dialysis patients, half-life is
prolonged to 2.6 and 52.7 h, respectively.21 A study on the
safety of Gd-containing contrast agents in 70 hemodialysis
patients with measurement of Gd excretory rates via
hemodialysis in 11 patients revealed an average rate of 78.2,
95.6, 98.7, and 99.5% in the first to fourth standard
hemodialysis session (i.e. 4 h sessions every other day,
three/week), respectively.22
Possible side effects occur owing to dissociation of the
gadolinium–ligand complex into metal ion and ligand. This
process is facilitated by endogenous metals like iron, zinc,
and copper, by calcium, and by endogenous acids.23 In renal
failure, there is common evidence of both metabolic acidosis
and absence of adequate clearance of Gd-containing contrast
agent.24 Free Gd solubility is poor, thereby favoring
formation of precipitates of salts with anions like phosphate,
carbonate, or hydroxyl. These salts may be deposited in
tissues like muscle, skin, liver, bone, and other organs.24
The majority of patients reported with NSF after contrast
MRI studies were administered gadodiamide.11,12 This may
be attributed, to some extent, to the fact that gadodiamide is
among the most widely used Gd-containing contrast agents,
especially in Europe. The molecular structure of chelate-
binding Gd in the case of gadodiamide is linear. It is a non-
tissue-specific and non-ionic low osmolar (780 mOsm/kg)
agent. As it is less stable, gadodiamide differs from most
other non-tissue-specific extracellular MRI contrast agents by
having an excess of chelate (Table 1). The high amounts of
chelate are added to overcome the problem of salt formation
and precipitation as outlined above, which may take place
with agents susceptible to transmetallation, that is release of
free Gd ion from the chelate and subsequent binding to
endogenous ions.25 Gadodiamide is almost exclusively
excreted renally and therefore has a markedly prolonged
half-life in patients with renal failure.26
GADOLINIUM-CONTAINING CONTRAST AGENTS AND NSF
After the description of NSF as a new entity, many speculated
on factors that might trigger or even cause the development
of this new disease.4,7–9 In January 2006 (electronic publica-
tion ahead of print), Grobner11 was the first to propose that
gadolinium-containing contrast media might trigger the
development of NSF. Five patients with end-stage renal
disease and hemodialysis were presented, all of whom had
developed NFD/NSF within 2–4 weeks after MRI with
gadodiamide. Besides administration of Gd-containing con-
trast media, the only other finding that all five patients had in
common was the presence of metabolic acidosis at the time of
MRI, while four other patients who had undergone MRI and
were not affected by NSF were not acidotic at the time of
examination. The average volume of gadodiamide used for
MRI in our patients was 35 ml (17.5 mmol). No other
exposure or common event could be identified.
A few months later, our findings were substantiated by
Marckmann et al.,12 who published a case series of 13
patients with end-stage renal disease and chronic hemodia-
lysis who had all been exposed to gadodiamide before the
development of NSF. The median time from gadodiamide
exposure to the first clinical signs of NSF noted was 25 days
(range 2–75 days). The average contrast volume was 38 ml
(19 mmol). An association with coexistent acidosis was not
seen. Development of NSF without prior gadolinium
administration was not observed by these authors and no
further cases of NSF were noted since the use of gadodiamide
was stopped in their unit. The most recent report from the
Loma Linda University Medical Center in California on 12
patients with NSF also concluded on a strong association
between development of NSF and gadodiamide administra-
tion, not only in dialysis patients (n¼ 8) but also in patients
with hepatorenal syndrome (n¼ 4).27
Table 1 | Characteristics of some gadolinium-containing contrast agents (FDA-approved)










Gadobenate-dimeglumine Gd-BOPTA MultiHances 1970 0.00 1018.4 Biliary/renal
Gadodiamide Gd-DTPA-BMA Omniscans 780 12.00 1014.9 Renal
Gadopentate-dimeglumine Gd-DTPA Magnevists 1940 0.40 1018.1 Renal
Gadoteridol Gd-HP-DO3A ProHances 630 0.23 1017.1 Renal
Gadoversetamide Gd-DTPA-BMEA Optimarks 1110 28.40 1015.0 Renal
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Evenepoel et al.28 also reported two cases of severe NSF in
2004. The unique and common factor for all three European
reports11,12,28 was that all patients had received gadodiamide.
In the United States, too, the majority of NSF patients have
received gadodiamide,27 with only a few patients who have
had other Gd-containing contrast agents (gadopentate or
gadoversetamide).
Another common feature of most of the affected patients
was the high dose of Gd-containing contrast agent used in
the patients reported, as most had magnetic resonance
angiograms where two- to threefold doses of Gd-containing
contrast agent were needed (0.2–0.3 mmol/kg body weight
instead of 0.1 mmol/kg with conventional MRI), a feature of
possible relevance in patients with impaired renal clearance.
To date, it is uncertain whether other Gd-based contrast
media are involved in some of the affected patients, but this is
a matter of current evaluation.26 The 2006 public health
advisory of the FDA on gadolinium use does not discriminate
between different Gd preparations at all, but recommends a
careful consideration of risks and benefits of MRI with Gd-
containing contrast agents and advises to choose alternative
imaging methods whenever possible.13
THE POSSIBLE LINK TO NSF
Recently, two independent study groups described gadoli-
nium to be detectable in skin and soft tissue specimens of
patients who had been administered Gd-containing contrast
agents and had NSF using the technique of scanning electron
microscopy (SEM) and energy dispersive X-ray spectroscopy
(EDS).29,30
Boyd et al.29 described SEM/EDS analyses in four patients
with NSF in whom linear Gd deposition was demonstrable in
dermal vessel walls and along the basal lamina of eccrine
sweat gland in areas with concomitant calcium–phosphate
deposition.
High et al.30 examined a single histologic section each of
specimens derived from seven NSF patients with prior
exposure to Gd. They demonstrated detectable Gd in four
patients and in all positive controls. No Gd was detected in a
random dermatopathology case specimen (without NSF)
serving as a negative control. In three of the four Gd-
containing specimens, the metal was confined to areas of
fibrosis. All Gd particles were less than 1 mm in diameter and
were located intracellular, possibly within lysosomes.
Additionally, they identified large deposits of iron in all
specimens and of other metals like copper, zinc, nickel, tin,
vanadium, and aluminum in some of them. The authors
speculate that the iron accumulation might possibly result
from contamination by the microtome blade itself, but may
also be due to iron administration to dialysis patients
eventually in large boluses.
Deposition of iron in the tissue as shown30 might be
favored by an iron-liberating effect of Gd-chelate with
elevation of free serum iron, especially in iron-overloaded
patients after Gd-containing contrast media examination.24
Free iron is highly toxic and, besides other effects, leads to
metabolic acidosis and might be an additional cofactor to
trigger fibrosis.
Although speculative to date, an interesting hypothesis
can be suggested on the role of circulating fibrocytes in the
context of the two studies on Gd deposition in NSF-affected
skin specimens.29,30 These recently characterized blood-borne
cells, circulating fibrocytes31 positive for CD34 and procolla-
gen and involved in wound healing, may invade the dermis
and differentiate to dermal cells, resembling functionally and
histologically normal fibroblasts, thereby inducing the
fibrosing process. Boyd et al.29 describe abundant CD34-
positive cells in their specimens, and High et al.30 discuss that
after transmetallation of Gd–chelate complexes, free Gd (and
other metals like iron) may be a target for these circulation
fibrocytes. Therefore, cutaneous Gd deposition may serve as a
nidus for the fibrosing process that leads to the development
of NSF.29
CONCLUSION
The recent finding of detectable Gd particles in skin
specimens of NSF patients is highly supportive of a strong
epidemiologic association between exposure to Gd-contain-
ing contrast agents and development of NSF as observed
clinically. The Gd ion with its calcium-mimicking effects and
the carrier molecule are likely to be involved in the
mechanisms that lead to NSF. Acidosis, although not a
conditio sine qua non, may be a state additionally favoring a
transmetallation process with liberation of free, toxic Gd ion.
The observed iron deposition in affected tissue could be
another cofactor for the development of fibrosis. Although
interesting new hypotheses on the cause of NSF are arising,
the pathomechanism of this disease is still unknown. Other
factors, for example the calcium–phosphorus–parathyroid
hormone metabolism, endothelial dysfunction, and others,
have to be studied. Besides, most but not all patients reported
with NSF were exposed to Gd-containing contrast agents.
Patients with NFD/NSF should be reported to the
National Medicines Agencies and International Registries
with a special view on a history of gadolinium exposure.
At this stage, the European Medical Agency has decided
that in patients with KDOQI-stage 4 and 5 chronic renal
disease (GFRo30 ml/min/1.73 m2), administration of
gadodiamide (Omniscans, Amersham Health, Norway,
Ireland) is contraindicated, and the use of other
Gd-containing contrast agents has to be critically weighed
against the possible risks. The FDA has given the following
public health advisory (recommendations and considera-
tions for healthcare professionals) for patients with moderate
(GFRo60 ml/min/1.73 m2) to end-stage renal disease
(GFRo15 ml/min/1.73 m2): ‘When recommending or per-
forming an MRI or MRA, carefully weigh the benefits and
risks associated with using a gadolinium-based contrast agent
in light of recent reports of NSF/NFD observed following
administration of these agents. Choose an alternative
imaging method and/or contrast agent whenever possible’
(Posted 8 January 2007).
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The latter recommendation may be interpreted as all Gd
preparations being contraindicated in patients with
GFRo30 ml/min/1.73 m2. Although no objective data are
available, we think that in patients with moderate renal
insufficiency (KDOQI stage 3: GFR 60–30 ml/min/1.73 m2),
performance of MRI with the use of gadolinium-containing
contrast agents should be carefully weighed against the risk to
develop NSF. Alternative imaging methods should be
considered whenever possible.
When inevitable nevertheless, the patient has to be
informed and MRI should be performed with the lowest
dose of Gd-containing contrast agent possible, only after
correction of acidosis and exclusion of iron overload. Again
not evidence based, in stage 3 kidney patients, an approach
could be chosen comparable to conventional iodinated
contrast media, namely hydration with 1 ml/kg body
weight/h of 0.9% saline solution 12 h before to 12 h after
the MRI examination to favor renal excretion of the Gd-
containing contrast agent. In stage 4 and 5 patients,
performance of up to four hemodialysis sessions should be
considered after Gd administration to eliminate the Gd-
containing contrast agent (see FDA advisory issued June
2006, updated December 2006 and January 2007).
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